Hong Kong stock anomaly | Haisco New Drug (02637.HK) rises over 10% to hit new high, nearly 70% higher than IPO price, with four core generic drugs contributing to 90% of revenue.

According to the Securities Times APP, Haixi Pharmaceuticals (02637.HK) rose more than 10% in the afternoon, reaching a high of 145.9 Hong Kong dollars, setting a new record high since listing, an increase of nearly 70% from the offer price of 86.4 Hong Kong dollars. As of the time of publication, it has risen by 10.87%, reaching 145.9 Hong Kong dollars, with a turnover of 16.7142 million Hong Kong dollars.